Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Discrete Changes in Glucose Metabolism Define Aging.

Ravera S, Podestà M, Sabatini F, Dagnino M, Cilloni D, Fiorini S, Barla A, Frassoni F.

Sci Rep. 2019 Jul 17;9(1):10347. doi: 10.1038/s41598-019-46749-w.

2.

Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells.

Rosso V, Panuzzo C, Petiti J, Carturan S, Dragani M, Andreani G, Fava C, Saglio G, Bracco E, Cilloni D.

J Clin Med. 2019 Jul 4;8(7). pii: E972. doi: 10.3390/jcm8070972.

3.

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C, Saglio G.

Int J Mol Sci. 2019 May 7;20(9). pii: E2249. doi: 10.3390/ijms20092249. Review.

4.

Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome? - Response to Lucijanic and Kusec.

Fabiani E, Valentini L, Cilloni D, Voso MT.

Br J Haematol. 2019 Aug;186(4):639-640. doi: 10.1111/bjh.15938. Epub 2019 May 1. No abstract available.

PMID:
31044416
5.

Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.

Petiti J, Rosso V, Lo Iacono M, Panuzzo C, Calabrese C, Signorino E, Pironi L, Cartellà A, Bracco E, Pergolizzi B, Beltramo T, Fava C, Cilloni D.

J Cell Mol Med. 2019 Jun;23(6):4349-4357. doi: 10.1111/jcmm.14326. Epub 2019 Apr 29.

6.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, Nierkens S, Jagasia M, Wagner JE, Kuball J, Koh LP, Majhail NS, Stiff PJ, Hanna R, Hwang WYK, Kurtzberg J, Cilloni D, Freedman LS, Montesinos P, Sanz G.

J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.

7.

Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.

Andreani G, Dragani M, Serra A, Nicoli P, De Gobbi M, Cilloni D.

Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29. No abstract available.

PMID:
30431666
8.

A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia.

Bernardoni R, Giordani G, Signorino E, Monticelli S, Messa F, Pradotto M, Rosso V, Bracco E, Giangrande A, Perini G, Saglio G, Cilloni D.

Haematologica. 2019 Apr;104(4):717-728. doi: 10.3324/haematol.2018.198267. Epub 2018 Nov 8.

9.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. No abstract available.

PMID:
30407614
10.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.

Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D.

Br J Haematol. 2018 Sep;182(5):701-704. doi: 10.1111/bjh.15450. Epub 2018 Jul 9.

PMID:
29984826
11.

Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells.

Ali MS, Gill KS, Saglio G, Cilloni D, Soden DM, Forde PF.

Bioelectrochemistry. 2018 Aug;122:84-92. doi: 10.1016/j.bioelechem.2018.03.009. Epub 2018 Mar 15.

12.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8.

PMID:
29520559
13.

Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.

Petiti J, Rosso V, Lo Iacono M, Calabrese C, Signorino E, Gaidano V, Berger M, Saglio G, Cilloni D.

Leuk Res. 2018 Apr;67:6-11. doi: 10.1016/j.leukres.2018.01.016. Epub 2018 Feb 5.

PMID:
29407184
14.

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.

La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A.

Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

15.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

16.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.

Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13.

17.

Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.

De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, La Rocca F, Caivano A, Villani O, Cilloni D, Musto P, Del Vecchio L.

Cell Death Dis. 2017 Jun 1;8(6):e2849. doi: 10.1038/cddis.2017.253.

18.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. No abstract available.

19.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

20.

Clonal haematopoiesis is not prevalent in survivors of childhood cancer.

Collord G, Park N, Podestà M, Dagnino M, Cilloni D, Jones D, Varela I, Frassoni F, Vassiliou GS.

Br J Haematol. 2018 May;181(4):537-539. doi: 10.1111/bjh.14630. Epub 2017 Apr 3. No abstract available.

21.

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.

Rosso V, Petiti J, Bracco E, Pedrola R, Carnuccio F, Signorino E, Carturan S, Calabrese C, Bot-Sartor G, Ronconi M, Serra A, Saglio G, Frassoni F, Cilloni D.

Oncotarget. 2017 Jan 24;8(4):6399-6405. doi: 10.18632/oncotarget.14113.

22.

Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.

Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G, Nicoli P, Gallo D, Bracco E, Morotti A, Panuzzo C, Gottardi E, Frassoni F, Saglio G, Cilloni D.

Oncotarget. 2016 Nov 8;7(45):74082-74096. doi: 10.18632/oncotarget.12269.

23.

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.

Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review.

24.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.

25.

The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.

Gallo D, Nicoli P, Calabrese C, Gaidano V, Petiti J, Rosso V, Signorino E, Carturan S, Bot-Sartor G, Volpe G, Frassoni F, Saglio G, Cilloni D.

Cancer Med. 2016 Jul;5(7):1650-3. doi: 10.1002/cam4.735. Epub 2016 May 11.

26.

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P.

Am J Hematol. 2016 Jul;91(7):681-6. doi: 10.1002/ajh.24377. Epub 2016 May 11.

27.

Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes.

Di Savino A, Gaidano V, Palmieri A, Crasto F, Volpengo A, Lorenzatti R, Scaravaglio P, Manello A, Nicoli P, Gottardi E, Saglio G, Cilloni D, De Gobbi M.

Br J Haematol. 2017 Feb;176(3):491-495. doi: 10.1111/bjh.13968. Epub 2016 Feb 23. No abstract available.

28.

MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation.

De Luca L, Trino S, Laurenzana I, Simeon V, Calice G, Raimondo S, Podestà M, Santodirocco M, Di Mauro L, La Rocca F, Caivano A, Morano A, Frassoni F, Cilloni D, Del Vecchio L, Musto P.

Oncotarget. 2016 Feb 9;7(6):6676-92. doi: 10.18632/oncotarget.6791.

29.

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.

Trino S, De Luca L, Simeon V, Laurenzana I, Morano A, Caivano A, La Rocca F, Pietrantuono G, Bianchino G, Grieco V, Signorino E, Fragasso A, Bochicchio MT, Venturi C, Rosti G, Martinelli G, Del Vecchio L, Cilloni D, Musto P.

Tumour Biol. 2016 Jan;37(1):217-25. doi: 10.1007/s13277-015-3772-9. Epub 2015 Jul 21.

PMID:
26194865
30.

Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH.

Rosso V, Bracco E, Pedrola R, Carturan S, Signorino E, Petiti J, Calabrese C, Nicoli P, De Gobbi M, Gaidano V, Gallo D, Ulisciani S, Fava C, Rege-Cambrin G, Frassoni F, Saglio G, Cilloni D.

Biomark Res. 2015 Jul 3;3:15. doi: 10.1186/s40364-015-0039-y. eCollection 2015.

31.

Development of cellular and humoral response against WT1 protein vaccination in mice.

Nicoli P, Calabrese C, Pellegrino RM, Rosso V, Bracco E, Signorino E, Carturan S, Petiti J, Gallo D, Gaidano V, De Gobbi M, Roetto A, Saglio G, Cilloni D.

Am J Hematol. 2015 Sep;90(9):E193-4. doi: 10.1002/ajh.24092. Epub 2015 Aug 14. No abstract available.

32.

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.

Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E.

BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9.

PMID:
25204541
33.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29.

PMID:
24994606
34.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
35.

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.

36.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT, Kosmider O, Fontenay M, Gozzini A, Bosi A, Santini V.

Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6.

37.

New possibilities to exploit the potentiality of cord blood cells in the context of transplantation.

Frassoni F, Cilloni D, Podestà M.

Immunol Lett. 2013 Sep-Oct;155(1-2):24-6. doi: 10.1016/j.imlet.2013.09.024. Epub 2013 Sep 27. Review. No abstract available.

PMID:
24080487
38.

Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms.

Bracco E, Rosso V, Serra A, Carnuccio F, Gaidano V, Nicoli P, Musto P, Saglio G, Frassoni F, Cilloni D.

BMC Cancer. 2013 Jul 18;13:348. doi: 10.1186/1471-2407-13-348.

39.

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.

Finazzi G, Vannucchi AM, Martinelli V, Ruggeri M, Nobile F, Specchia G, Pogliani EM, Olimpieri OM, Fioritoni G, Musolino C, Cilloni D, Sivera P, Barosi G, Finazzi MC, Di Tollo S, Demuth T, Barbui T, Rambaldi A.

Br J Haematol. 2013 Jun;161(5):688-94. doi: 10.1111/bjh.12332. Epub 2013 Apr 10.

PMID:
23573950
40.

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia.

Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G.

Leuk Res. 2013 May;37(5):520-30. doi: 10.1016/j.leukres.2013.01.014. Epub 2013 Feb 12.

PMID:
23415111
41.

Cardiovascular events and intensity of treatment in polycythemia vera.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.

N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.

42.

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.

Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A.

J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.

43.

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.

Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G.

Haematologica. 2013 Feb;98(2):193-200. doi: 10.3324/haematol.2012.066480. Epub 2012 Aug 8.

44.

Quality of life and physicians' perception in myelodysplastic syndromes.

Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA.

Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25.

45.

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP.

Haematologica. 2012 Jun;97(6):907-14. doi: 10.3324/haematol.2011.056457. Epub 2011 Dec 29.

46.

Molecular pathways: BCR-ABL.

Cilloni D, Saglio G.

Clin Cancer Res. 2012 Feb 15;18(4):930-7. doi: 10.1158/1078-0432.CCR-10-1613. Epub 2011 Dec 8. Review.

47.

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).

Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E, Di Raimondo F, Fozza C, Annino L, Chiarini F, Ricci F, Ammatuna E, La Sala E, Fazi P, Vignetti M.

Br J Haematol. 2012 Jan;156(2):205-12. doi: 10.1111/j.1365-2141.2011.08940.x. Epub 2011 Nov 15.

PMID:
22082314
48.

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.

Alimena G, Breccia M, Musto P, Cilloni D, D'Auria F, Latagliata R, Sanpaolo G, Gottardi E, Saglio G, Mandelli F.

Leuk Res. 2011 Apr;35(4):504-7. doi: 10.1016/j.leukres.2010.08.021. Epub 2010 Oct 23.

PMID:
20971509
49.

Emerging targets for hematological malignancies.

Cilloni D, Frassoni F, Saglio G.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):548-58. Review.

PMID:
20812146
50.

Iron chelation therapy in myelodysplastic syndromes.

Messa E, Cilloni D, Saglio G.

Adv Hematol. 2010;2010:756289. doi: 10.1155/2010/756289. Epub 2010 Jun 20.

Supplemental Content

Loading ...
Support Center